AbCellera Biologics (ABCL) Short-Term Debt issuances (2020)

AbCellera Biologics (ABCL) posted Short-Term Debt issuances of -$774000.0 for Q4 2020, down 300.0% on a QoQ basis from $387000.0 in Q1 2020.

AbCellera Biologics (ABCL) Short-Term Debt issuances (2020) Analysis & Trends

AbCellera Biologics' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at -$774000.0 for Q4 2020.

Quarterly Short-Term Debt issuances changed N/A year-over-year to -$774000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$387000.0 (changed N/A YoY) and the FY2020 annual result came in at -$387000.0, down 200.0% from the prior year.
Short-Term Debt issuances was -$774000.0 for Q4 2020 at AbCellera Biologics, down from $387000.0 in the prior quarter.
Across five years, Short-Term Debt issuances topped out at $387000.0 in Q1 2020 and bottomed at -$774000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	102,000.00
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	58.20 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	AbCellera Biologics	1.61 Bn	1.61 Bn	-	-

Download Data